Tempus AI Acquires Paige for $81Mn to Expand Digital Pathology

The acquisition is expected to expand Tempus’ technical team and establish a stronger presence in digital pathology.

AI-powered data company Tempus AI announced it will acquire Paige, an AI-enabled diagnostic platform for oncologists and pathologists, for $81.25 million. 

The acquisition is expected to expand Tempus’ technical team and establish a stronger presence in digital pathology.

Tempus’ platform provides healthcare providers access to patient data, including lab tests, and streamlines the ordering of DNA, RNA, and biomarker tests tailored to cancer types. Its Tempus One AI-enabled clinical assistant offers insights into patient treatment and medical information.

Paige’s platform provides access to millions of digitized pathology slides, clinical reports, and genomic data. Its AI-assisted diagnostic application helps pathologists identify and classify cancer. Eric Lefkofsky, founder and CEO of Tempus, said, “We believe both the Paige team, with their deep generative AI experience and the dataset they have built, will be catalytic across all of our AI efforts.”

Acquisition Context and Financial Developments

Tempus’ recent developments highlight growing institutional interest. Jump Financial acquired 177,135 shares of Tempus AI stock valued at approximately $8.55 million, while major investors, including ARK Investment Management and Vanguard Group, have increased holdings. The company’s stock trades around $76 per share.

The acquisition follows Tempus’ FDA 510(k) clearance in July for its Tempus ECG-Low EF software, which uses AI to identify patients with low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared AI ECG device in the company’s portfolio for identifying cardiovascular risk.

Additionally, Tempus expanded its care pathway intelligence platform, Tempus Next, into breast cancer, addressing five biomarker testing gaps to support guideline-directed medical care. In June, Tempus collaborated with the Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to apply AI analytics to Alzheimer’s disease genomic data.

Paige’s Ongoing Contributions in Oncology

Paige continues to advance AI applications in oncology. In July, it released PRISM2, a slide-level foundation model designed to enhance large language models by connecting visual pathology patterns with clinical language. The company also partnered with the Breast International Group to improve breast cancer diagnosis, treatment, and patient outcomes.

Paige’s AI software received FDA de novo marketing authorization in 2021 for prostate cancer detection, analyzing digitized biopsy slides to highlight potentially cancerous areas for pathologist review.

Stay tuned for more such updates on Digital Health News